Myriad Genetics Showcases New Research and Product Innovatio

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven

Related Keywords

Japan , Salt Lake City , Utah , United States , Texas , George Daneker Jr , Matt Scalo , Bracanalysis Cdx , Hollyj Pederson , Glenn Farrell , Breast Services , Oncology Solutions , Nasdaq , Memorial Sloan Kettering Cancer Center , Collaborative Research Registry , Genetics Inc , National Cancer Center Hospital , Exchange Commission , University Of Texas Md Anderson Cancer Center , A Myriad Collaborative Research Registry Study , Diagnostic Test , Myriad Collaborative Research Registry , Medical Breast Services , Germline Genetic Profiles , Ovarian Malignancies , Myriad Collaborative Research Registry Study , Uterine Cancer , Hereditary Cancer Test , Tumor Test , Prostate Cancer Prognostic Test , Breast Cancer Prognostic Test , Folate Receptor Alpha , Germline Companion Diagnostic , Cancer Center , National Cancer Center Hospital East , Intermountain Precision Genomic , Precise Tumor , Precise Liquid , Myriad Genetics , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports ,